发明名称 Agent for improving vesicourethral dyssynergia
摘要 This invention is directed to an ameliorating agent for a disease based on vesicourethral dyssynergia, comprising, as an active ingredient, 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof. The disease based on vesicourethral dyssynergia is any of dysuria accompanying a lifestyle-related disease (such as diabetic dysuria), idiopathic dysuria, dysuria after pelvic surgery, dysuria accompanying spinal cord injury, dysuria accompanying spinal canal stenosis, dysuria accompanying benign prostatic hypertrophy, dysuria accompanying high-pressure voiding/high-pressure urine storage, neurogenic or nonneurogenic lower urinary tract symptoms (LUTS), detrusor sphincter dyssynergia, and detrusor bladder neck dyssynergia.
申请公布号 US9271948(B2) 申请公布日期 2016.03.01
申请号 US201414496281 申请日期 2014.09.25
申请人 Taiho Pharmaceutical Co., Ltd. 发明人 Hayashi Yukio;Hakozaki Atsushi
分类号 A61K31/122 主分类号 A61K31/122
代理机构 Rothwell, Figg, Ernst & Manbeck, P.C. 代理人 Rothwell, Figg, Ernst & Manbeck, P.C.
主权项 1. A method for treating detrusor sphincter dyssynergia in a patient in need thereof, comprising the step of administering a therapeutically effective amount of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof to said patient.
地址 Tokyo JP